Top Stories: Dicerna Pharmaceuticals (NASDAQ:DRNA), Merck & Co. Inc. (NYSE:MRK), Apple Inc. (NASDAQ:AAPL), News Corporation (NASDAQ:NWSA), Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)

On Monday shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) closed at $20.27. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced the commencement of a proposed underwritten public offering of 2,750,000 shares of common stock. Dicerna also intends to grant the underwriters a 30-day option to purchase up to an additional 412,500 shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

On Monday shares of Merck & Co. Inc. (NYSE:MRK) closed at $60.01. Company’s sales growth for last 5 years was 9.00% and EPS growth for next 5 years is recorded as 4.39%. German drug maker Merck & Co. Inc. (NYSE:MRK) reported that first-quarter net income declined 13.1 percent to 281.7 million euros or 0.65 euros per share from 325.2 million euros or 0.75 euros per share in the prior-year quarter.

Apple Inc. (NASDAQ:AAPL) in last trading activity moved up 1.10% to close at $130.19. Company weekly performance is 3.06% while its quarterly performance stands at 2.27%. Apple Inc. (NASDAQ:AAPL) is -2.83% away from its 52 week high. A federal appeals court handed a partial victory to Apple Inc. (NASDAQ:AAPL) upholding court findings smartphone rival Samsung Electronics Co. infringed the iPhone maker’s intellectual property but setting aside part of a $930 million jury award.

News Corporation (NASDAQ:NWSA) has 0.77% insider ownership while its institutional ownership stands at 99.40%. In last trading activity company’s stock closed at $15.68. On May 10, News Corp announced that it has begun repurchasing shares of Class A Common Stock under its previously disclosed buyback program. This marks the first time the company has bought back stock under the program since the “new” News Corp was established as a separate, publicly-traded company in mid-2013.

On last trading day Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) fell -1.42% to close at $6.26. Its volatility for the week is 4.32% while volatility for the month is 4.87%. Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) monthly performance is 0.97%. On May 13, Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) announced that it has begun a Phase 3 clinical study of TNX-102 SL (cyclobenzaprine HCl sublingual tablet, 2.8 mg) in fibromyalgia, having recently randomized the first patient. The study is expected to enroll approximately 500 patients with fibromyalgia at approximately 35 clinical centers in the U.S.

Leave a Reply

Your email address will not be published. Required fields are marked *